Transdermal Scop® patches

The most popular use of scopolamine today is for the prevention of motion sickness via the Transderm-Scop patch. This device delivers about 0.5 mg of the drug over a three day period. Scopolamine and other drugs in this class can accumulate in significant quantities in the blood and some can cause CNS effects such as drowsiness, dry mouth and blurry vision. In rare cases amnesia and even psychosis can occur. The sedation and dry mouth are useful effects in that some of the compounds are used as tranquilizers and to dry up the mouth prior to anesthesia. 

The popular Transdermal Scop patches are widely used by travelers who experience motion sickness, and contain 1.5 mg of scopolamine solubilized to approximately 100 mg/ml in mineral oil, and deliver 1.0 mg over three days. Catapres -TTS patches contain 2.5-7.5 mg of clonidine solubilized in mineral oil, and deliver 0.1-0.3 mg/day for seven days. Vivelle-DOT patches contain 0.39-1.6 mg of estradiol solubilized in... 

Trade names Isopto Hyoscine Ophthalmic Scopace Scopase Scopoderm-TTS Transderm-Scop Patch (Novartis) ... 

Transderm-Scop Patch scopolamine Tridol tramadol... 

Transdermal (Transderm Scop) 1.5 mg (delivers 0.5 mg/24 h) patch Solifenacin (Vesicare)... 

Transdermal Transderm-Scop transdermal patch system Catapres-TTS transdermal system... 

Scopolamine was the first drug to be marketed as a transdermal delivery system (Transderm-Scop) to alleviate the discomfort of motion sickness. After oral administration, scopolamine has a short duration of action because of a high first-pass effect. In addition, several side-effects are associated with the peak plasma levels obtained. Transderm-Scop is a reservoir system that incorporates two types of release mechanims a rapid, short-term release of drag from the adhesive layer, superimposed on an essentially zero-order input profile metered by the microporous membrane separating the reservoir from the skin surface. The scopolamine patch is able to maintain plasma levels in the therapeutic window for extended periods of time, delivering 0.5 mg over 3 days with few of the side-effects associated with (for example) oral administration. 

Membrane-moderated patches have been utilized in many FDA-approved transdermal patches such as Duragesic, Transderm Scop, and Catapress TTS. This type of patch utilizes a rate-controlling membrane to precisely control the release of... 

In 1978 Tranderm Scop was the first transdermal patch to receive FDA approval. Scopolamine, the active ingredient, is a belladonna alkaloid that is frequently used to treat motion sickness and nausea resulting from anesthetics and analgesics. Transderm Scop is a membrane-moderated patch that has a three-day life span. It has a circular shape with an area (2.5 cm2) approximately the size of a quarter [26]. 

Transderm Scop (scopolamine) 2-day patch for prevention of nausea and vomiting associated with motion sickness. 

Scopolamine (Transderm Scop) 0.5 mg every 72 h prn Transdermal patch Rx... 

Transderm-Scop Alza/Novartis Reservoir type A mineral oil is used as the reservoir. It uses a controlled release dmg membrane. It is used once a day. It is patched behind the ear where absorption is rapid. There is a side effect if the patient forgets to remove the patch. 

The most commonly used muscarinic receptor antagonist is scopolamine (hyoscine), which usually is administered as the free base in the form of a transdermal patch (transdee(M-scop). Its principal utility is in the prevention and treatment of motion sickness, although it also has some activity in postoperative nausea and vomiting. In general, anticholinergic agents have no role in chemotherapy-induced nausea. 

---